Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.
Publication
, Journal Article
Abdelmotilib, H; West, AB
Published in: Genome Med
October 19, 2017
Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson's disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease.
Duke Scholars
Published In
Genome Med
DOI
EISSN
1756-994X
Publication Date
October 19, 2017
Volume
9
Issue
1
Start / End Page
88
Location
England
Related Subject Headings
- alpha-Synuclein
- Parkinson Disease
- Humans
- Drug Delivery Systems
- Antiparkinson Agents
- Adrenergic beta-2 Receptor Agonists
- 3105 Genetics
- 1103 Clinical Sciences
- 0604 Genetics
Citation
APA
Chicago
ICMJE
MLA
NLM
Abdelmotilib, H., & West, A. B. (2017). Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy. Genome Med, 9(1), 88. https://doi.org/10.1186/s13073-017-0483-4
Abdelmotilib, Hisham, and Andrew B. West. “Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.” Genome Med 9, no. 1 (October 19, 2017): 88. https://doi.org/10.1186/s13073-017-0483-4.
Abdelmotilib H, West AB. Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy. Genome Med. 2017 Oct 19;9(1):88.
Abdelmotilib, Hisham, and Andrew B. West. “Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.” Genome Med, vol. 9, no. 1, Oct. 2017, p. 88. Pubmed, doi:10.1186/s13073-017-0483-4.
Abdelmotilib H, West AB. Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy. Genome Med. 2017 Oct 19;9(1):88.
Published In
Genome Med
DOI
EISSN
1756-994X
Publication Date
October 19, 2017
Volume
9
Issue
1
Start / End Page
88
Location
England
Related Subject Headings
- alpha-Synuclein
- Parkinson Disease
- Humans
- Drug Delivery Systems
- Antiparkinson Agents
- Adrenergic beta-2 Receptor Agonists
- 3105 Genetics
- 1103 Clinical Sciences
- 0604 Genetics